理解肌层浸润性膀胱癌患者对自身管理的看法
通过BCAN网站先后于2013年8月至2014年9月(队列A,243例)和2023年6月至2024年4月(队列B,94例)发放32题问卷,评估患者从症状到诊断治疗的时间、多学科评估及满意度。结果显示两队列分别有35%与30%等待超过3个月才就医、38%与43%超过3个月才获得诊断,男性在1-2个月内诊断的比例均高于女性,术前放疗科会诊与保留膀胱治疗不常见。
要点
- 两队列分别有35%与30%等待超过3个月才就医(P=0.56),38%与43%超过3个月才获得诊断(P=0.76)。
- 男性较女性更可能在1-2个月内诊断:队列A 68% vs 47%(P=0.03),队列B 70% vs 37%(P=0.03)。
- 术前放疗科会诊与保留膀胱治疗不常见,队列A 77% vs 队列B 67%认为有足够时间做决定(P=0.004)。
核心结论
- 肌层浸润性膀胱癌存在未满足需求,包括缩短确定性诊断与治疗时间(尤其女性)及增加确定性手术前的多学科评估。
- 受访者为自我选择、能访问BCAN网站且受教育程度高,可能限制结果的普适性。
研究设计与样本
- 由医生、护士、患者和照护者参与制定32题问卷,张贴于BCAN网站。
- 队列A招募时间为2013年8月至2014年9月,队列B为2023年6月至2024年4月。
- 共337例自我选择的患者完成调查,多为美国或加拿大白人男性,至少本科学历;队列A 243例,队列B 94例。
- 诊断时中位年龄(范围)队列A为61(31-93)岁,队列B为63(38-87)岁。
主要发现
- 最常见首发症状为血尿。
- 等待超过3个月才就医:队列A 35% vs 队列B 30%(P=0.56)。
- 超过3个月才获得诊断:队列A 38% vs 队列B 43%(P=0.76)。
- 男性较女性更可能在1-2个月内诊断:队列A 68% vs 47%(P=0.03),队列B 70% vs 37%(P=0.03)。
- 认为有足够时间做决定:队列A 77% vs 队列B 67%(P=0.004);多数患者对治疗选择满意。
局限性
- 受访者为自我选择,能访问BCAN网站且受教育程度高,可能限制结果的普适性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the impact of advocacy efforts by organisations such as the Bladder Cancer Advocacy Network (BCAN) to increase awareness about the signs, symptoms, diagnosis, treatment and need for a multidisciplinary approach to the care of patients with muscle-invasive bladder cancer (MIBC). MATERIALS AND METHODS: We developed a 32-question survey with input from physicians, nurses, patients and caregivers. The survey was posted on the BCAN website between August 2013 and September 2014 (Cohort A) and again between June 2023 and April 2024 (Cohort B). Questions focused on time from initial symptoms to diagnosis and treatment, proportion seeing a medical oncologist or radiation oncologist, treatments offered/received, and patient satisfaction with their treatment choices. RESULTS: Overall, 337 self-selected patients mostly white males from the US or Canada, with at least an undergraduate education completed the survey. There were 243 patients in Cohort A and 94 patients in Cohort B. The median age (range) at diagnosis was 61 (31-93) in Cohort A and 63 (38-87) in Cohort B. The most common presenting symptom was hematuria. In Cohorts A and B, 35% vs 30% (P = 0.56) waited >3 months to seek medical attention, and in 38% vs 43% (P = 0.76) it took >3 months to obtain a diagnosis. Men were more likely than women to be diagnosed within 1-2 months in both cohorts (Cohort A: 68% vs 47%; P = 0.03, Cohort B: 70% vs 37%; P = 0.03). Preoperative consultation with a radiation oncologist and bladder-sparing use were infrequent. More patients in Cohort A (77%) felt they had enough time to make decisions compared to Cohort B (67%) (P = 0.004). Most patients were satisfied with their treatment choices. CONCLUSIONS: There are ongoing areas of unmet need in MIBC, including reducing time to definitive diagnosis and treatment, especially in women, and increasing multidisciplinary assessments prior to definitive surgery. Respondents were self-selected, had access to the BCAN website, and were highly educated, potentially limiting the generalizability of these results.
引用
- Chowdhury D, Apolo AB, Jiang DM, et al. Understanding patient perspectives in the management of their muscle-invasive bladder cancer. BJU Int. 2025. PMID: 40047292. doi:10.1111/bju.16695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。